This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Therapeutic Advances and Evolving Treatment Strategies: Novel Approaches to Migraine Management

Therapeutic Advances and Evolving Treatment Strategies: Novel Approaches to Migraine Management

Format

Slide Lecture Series

Time to Complete

1 hour

Released

July 10, 2017

Expires

July 10, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM
1.00 / CNE for Nurses
1.00 / CE for Pharmacists (0.10 CEUs)

Accredited Provider



Provided by MediCom Worldwide, Inc.

Commercial Supporter

This activity is supported by an educational grant from Teva Pharmaceuticals.

Program Description

Exciting clinical trials are underway which show great promise in narrowing the unmet clinical need in the preventive treatment of migraine. Data suggest that calcitonin gene-related peptide (CGRP) inhibitors are going to usher in a new era in treatment. How will these novel agents affect your practice?

Our nationally renowned faculty present the most up-to-date information and data being reported in clinical trials for the new CGRP inhibitors. Whether you’re learning this information for the first time or you want to hear the newest information about how CGRP inhibitors will change your practice, this program will provide you with new insight into how what’s happening in clinical trials today will impact your practice in the near future.

This enduring program was streamed live from the 59th Annual Scientific Meeting - American Headache Society.

Intended Audience

This activity is designed for neurologists, primary care clinicians, nurses, and pharmacists specializing in headache management.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Correlate current challenges and unmet needs in migraine prevention with the clinical impact on patients
  • Describe the mechanism of action of CGRP, relating how CGRP-based therapies will impact the pathophysiologic development of migraine
  • Summarize data focusing on emerging novel agents for preventive treatments associated with episodic and chronic migraine

Conflict Of Interest Disclosure Policy

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty

David W. Dodick, MD – Chair
Professor of Neurology
Department of Neurology
Mayo Clinic
Phoenix, AZ

Dr. Dodick has received honoraria as a consultant from Acorda, Alder BioPharmaceuticals Inc., Allergan, Inc., Amgen Inc., Autonomic Technologies, Inc., Boston Scientific Corporation, CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, eNeura Inc., GBS Ventures, Insys Therapeutics, Inc., Merck & Co., Inc., Promius Pharma, LLC., TEVA Pharmaceutical LTD, Tonix Pharmaceuticals Holding Corp., Trigemina, Inc., Xenon Pharmaceuticals Inc., and Zosano Pharma Corporation. He has received royalties from Cambridge University Press and Oxford University Press. He has stock options with EPIEN Medical, Inc., GBS/Nocira, and Mobile Health, and has a consulting use agreement with NAS.

Alan M. Rapoport, MD
Clinical Professor of Neurology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Dr. Rapoport has received honoraria as a consultant from Acorda, Autonomic Technologies, Inc., Avanir Pharmaceuticals, Inc., Depomed, Inc., Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Impax Laboratories, Inc., PERNIX Therapeutics, TEVA Pharmaceutical LTD, and Zosano Pharma Corporation, as well as honoraria related to speakers’ bureau activities from Avanir and Depomed.

Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, NH

Dr. Tepper has received honoraria as a consultant from Acorda, Alder BioPharmaceuticals Inc., Allergan, Inc., Amgen Inc., ATI, Avanir Pharmaceuticals, Inc., BioVision Inc., electroCore, LLC, Eli Lilly and Company, eNeura Inc., Kimberly-Clark, PERNIX Therapeutics, Pfizer Inc., TEVA Pharmaceutical LTD, and Zosano Pharma Corporation; and honoraria related to formal advisory activities from Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy’s Laboratories Ltd., Kimberly-Clark, Scion NeuroStim, TEVA, and Pfizer Inc. Dr. Tepper has also received royalties or licensing fees from Springer and the University of Mississippi Press. He has disclosed a financial relationship with the American Headache Society, Dartmouth-Hitchcock Medical Center, and has stock options with ATI.

Planning Committee Disclosure

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity:
Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380.

Designation Statement

MediCom designates this CNE activity for 1.00 contact hour. Program Number: 17-159-059

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

MeediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity is acceptable for 1.00 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-17-159-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Hutchinson has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US. Dr. Hutchinson has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue